| Field | Specification |
|---|---|
| Target | |
| Alternative names | Tilarginine acetate; Methylarginine acetate |
| CAS no. | |
| Applications | |
| Source | Endogenous metabolite |
| Molecular weight | |
| Molecular formula | C9H20N4O4 |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
L-NMMA acetate, also known as Tilarginine acetate and Methylarginine acetate, is a non-selective, competitive inhibitor of nitric oxide synthase. It inhibits three subtypes, namely nNOS, eNOS, and iNOS, and reduces NO production, and it alleviates mechanical allodynia, thermal hyperalgesia, and choroidal fibrosis. It is applicable to research related to nociception, bone cancer pain, and myopia[1][2][3]. It is supplied as a white to off-white solid (C9H20N4O4, MW 248.28) at 99.95% purity.
Physical & Chemical Properties
| CAS Number | 53308-83-1 |
|---|---|
| Molecular Formula | C9H20N4O4 |
| Molecular Weight | 248.28 g/mol |
| Purity | 99.95% |
| Appearance | Solid |
| Color | White to off-white |
| Structure Classification | Others |
| SMILES | N[C@@H](CCCNC(NC)=N)C(O)=O.O=C(C)O |
| Target | eNOS, iNOS, nNOS |
| Signaling Pathway | Immunology/Inflammation |
| Initial Source | Endogenous metabolite |
| Solubility | In Vitro: H2O: ≥ 50 mg/mL (201.39 mM) * "≥" means soluble, but saturation unknown. |
| Storage | 4°C, sealed storage, away from moisture. In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| H2O | ≥ 50 mg/mL (201.39 mM) | — |
Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); sealed storage, away from moisture; avoid repeated freeze-thaw cycles.
If water is used as the stock solvent, dilute to the working solution and sterilize it through a 0.22 μm filter before use.
In Vivo
Choose the formulation that suits the animal model and route of administration. Percentages are volume ratios of the final working solution. Prepare the working solution fresh on the day of dosing; if precipitation or phase separation occurs, gentle warming or sonication can help.
Direct preparation of the working solution
These formulations are prepared directly, without a DMSO stock; use them promptly after preparation.
Protocol 1
| Composition | PBS |
|---|---|
| Result | 100 mg/mL (402.77 mM); clear solution; requires sonication |
Data provided by the manufacturer.
In Vivo
In mice, bone cancer-induced mechanical allodynia and thermal hyperalgesia are significantly alleviated at 2 and 12 h post-treatment by L-NMMA (50 μg; i.t.; single administration) acetate[1]. In lens-induced myopic guinea pigs, L-NMMA (20 nmol; intravitreal injection, once every other day; 2 to 4 weeks) acetate relieves choroidal fibrosis and delays myopia progression by inhibiting the NO signaling pathway[2].
| Animal Model | C3H/HeJ (male, 4-6 weeks old, 20-22 g, intramedullary inoculation of NCTC 2472 osteosarcoma cells)[1] |
|---|---|
| Dosage | 50 μg |
| Administration | i.t.; single administration |
| Result | Increased paw withdrawal mechanical threshold to 0.90 g at 2 h and 0.63 g at 12 h compared to 0.40 g in vehicle-treated tumor mice. Increased paw withdrawal thermal latency to 16.2 sec at 2 h and 12.7 sec at 12 h compared to 10.1 sec in vehicle-treated tumor mice. Lost analgesic effect at 24 h post-administration. |
| Animal Model | British short-haired tricolor guinea pigs (2-week-old, 110-130 g, lens-induced myopia model)[2] |
|---|---|
| Dosage | 20 nmol |
| Administration | intravitreal injection; once every other day; 2 and 4 weeks |
| Result | Increased refraction significantly after 2 and 4 weeks compared to the lens-induced myopia group. Reduced the D-value of axial length between the myopic eye and control eye significantly after 2 and 4 weeks compared to the lens-induced myopia group. Increased choroidal thickness to 80.62 μm at 4 weeks compared to 63.54 μm in the lens-induced myopia group. Reduced degradation of choroidal pigment particles and narrowed particle gaps compared to the lens-induced myopia group. Produced denser, more orderly choroidal tissue structure compared to the lens-induced myopia group. Reduced choroidal fibrosis compared to the lens-induced myopia group. Lowered gene expression levels of NOS1, NOS3, TGF-β1, COL I, and α-SMA significantly after 2 and 4 weeks compared to the lens-induced myopia group. Lowered protein levels of NOS1, NOS3, TGF-β1, COL I, and α-SMA significantly after 2 and 4 weeks compared to the lens-induced myopia group. Reduced expression of COL I, α-SMA, NOS1, NOS3, and TGF-β1 in choroidal tissues compared to the lens-induced myopia group. |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
Lighting up arginine metabolism reveals its functional diversity in physiology and pathology. Cell Metab 2025 Jan 7;37(1):291-304.e9. PMID: 39413790
Ammonia detoxification promotes CD8+ T cell memory development by urea and citrulline cycles. Nat Immunol 2023 Jan;24(1):162-173. PMID: 36471170
An infection-induced RhoB-Beclin 1-Hsp90 complex enhances clearance of uropathogenic Escherichia coli. Nat Commun 2021 May 10;12(1):2587. PMID: 33972537
Citrulline inhibits Clostridioides difficile infection with anti-inflammatory effects. Cell Mol Gastroenterol Hepatol 2025;19(6):101474. PMID: 39923847
Fibrinogen/AKT/Microfilament Axis Promotes Colitis by Enhancing Vascular Permeability. Cell Mol Gastroenterol Hepatol 2021;11(3):683-696. PMID: 33075564
Identification and regulation of a novel leptin receptor-linked enhancer during zebrafish ventricle regeneration. Life Sci 2025 Feb 15:363:123415. PMID: 39864617
Tudor-based proteomic strategy pan-specifically enriches and identifies protein arginine methylation. EMBO Rep 2025 Oct 20. PMID: 41116072
mTOR Signaling Regulates the Development and Therapeutic Efficacy of PMN-MDSCs in Acute GVHD. Front Cell Dev Biol 2021 Dec 23;9:741911. PMID: 35004668
Spatial Metabolism of Primary Limited Cutaneous Amyloidosis Based on Mass Spectrometry Imaging. FASEB J 2025 Sep 30;39(18):e71057. PMID: 40955599
Fibroblast transdifferentiation promotes conversion of M1 macrophages and replenishment of cardiac resident macrophages following cardiac injury in mice. Eur J Immunol 2020 Jun;50(6):795-808.
